[1]陈万春,张思维,郑荣寿,等.中国肿瘤登记地区2007年肿瘤发病和死亡分析.中国肿瘤,2011,20:162-169. [2]Streeter OE Jr,Martz KL,Gaspar LE,et al. Does race influence survival for esophageal cancer patients treated on the radiation and chemotherapy arm of RTOG 85-01? Int J Radiat Oncol Biol Phys,1999,44:1047-1052. [3]李巧巧,胡永红,刘孟忠,等.放疗同期多西紫杉醇和顺铂化疗不能手术食管癌的疗效观察.中华放射肿瘤学杂志,2009,18:379-382. [4]张晓东,沈琳,李洁,等.放化疗联合与单独化疗对晚期食管癌生存期影响的比较.中华肿瘤杂志,2007,29:474-477. [5]Syrigos KN,Zalonis A,Kotteas E,et al. Targeted therapy for oesophageal cancer: an overview. Cancer Metastasis Rev,2008,27:273-288. [6]Yang YL,Xu KL,Zhou Y,et al. Correlation of epidermal growth factor receptor overexpression with increased epidermal growth factor receptor gene copy number in esophageal squamous cell carcinomas. Chin Med J,2012,125:450-454. [7]Boone J,van Hillegersberg R,Offerhaus GJ,et al. Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Dis Esophagus,2009,22:496-504. [8]Yu WW,Guo YM,Zhu M,et al. Clinicopathological and prognostic significance of EGFR over-expression in esophageal squamous cell carcinoma: a meta-analysis. Hepatogastroenterology,2011,58:426-431. [9]Gong JH,Liu XJ,Li Y,et al. Pingyangmycin downregulates the expression of EGFR and enhances the effects of cetuximab on esophageal cancer cells and the xenograft in athymic mice. Cancer Chemother Pharmacol,2012,69:1323-1332. [10]Yarden Y,Sliwkowski X. Undstandling the ErbB signaling network. Nat Rev Mol Cell Biol,2001,2:127-137. [11]Sato-Kuwabara Y,Neves JI,Fregnani JH,et al. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ hybridization(FISH) and immunohistochemistry. BMC Cancer,2009,9:6. [12]Takala H,Saarnio J,Wiik H,et al. HIF-1αand VEGF are associated with disease progression in esophageal carcinoma. J Surg Res,2011,167:41-48. [13]Prins MJ,Verhage RJ,ten Kate FJ,et al. Cyclooxygenase isoenzyme-2 and vascular endothelial growth factor are associated with poor prognosis in esophageal adenocarcinoma. J Gastrointest Surg,2012,16:956-966. [14]Lu TY,Li WC,Chen RY,et al. Inhibition effects of all trans-retinoic acid on the growth and angiogenesis of esophageal squamous cell carcinoma in nude mice. Chin Med J,2011,124:2708-2714. [15]Liu JF,Jamieson G,Wu TC,et al. Cyclooxygenase-2 expression in squamous cell carcinoma of the esophagus. Dis Esophagus,2006,19:350-354. [16]吴慧,卢晓旭,刘冬梅,等.小干扰RNA沉默cox-2表达增强食管癌EC9706细胞的放射敏感性.中华医学杂志,2012,92:1621-1625. [17]Fukuchi M,Fukai Y,Kimura H,et al. Prolyl isomerase Pin1 expression predicts prognosis in patients with esophageal squamous cell carcinoma and correlates with cyclinD1 expression. Int J Oncol,2006,29:329-334. [18]Sato S,Kajiyama Y,Sugano M,et al. Alvocidib(Flavopiridol) suppresses tumor growth in SCID mice with human esophageal cancer xenografts without inducing apoptosis. Surg Oncol,2006,15:107-113. [19]Miura K,Fujibuchi W,Ishida K,et al. Inhibitor of apoptosis protein family as diagnostic markers and therapeutic targets of colorectal cancer. Surg Today,2011,41:175-182. [20]Kelly RJ,Lopez-Chavez A,Citrin D,et al. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin. Mol Cncer,2011,10:35. [21]Takeno S,Yamashita S,Takahashi Y,et al. Survivin expression in oesophageal squamous cell carcinoma: its prognostic impact and splice variant expression. Eur J Cardiothorac Surg,2010,37:440-445. [22]Ellis L,Hammers H,Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett,2009,280:145-153. [23]Zhu H,Feng Y,Zhang J,et al. Inhibition of hypoxia inducible factor 1α expression suppresses the progression of esophageal squamous cell carcinoma. Cancer Biol Ther,2011,11:981-987. [24]Jing SW,Wang YD,Kuroda M,et al. HIF-1α contributes to hypoxia-induced invasion and metastasis of esophageal carcinoma via inhibiting E-cadherin and promoting MMP-2 expression. Acta Med Okayama,2012,66:399-407. [25]Lorenzen S,Schuster T,Porschen R,et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase Ⅱ study of the arbeitsgemeinschaft internistische onkologie. Ann Oncol,2009,20:1667-1673. [26]Tomblyn MB,Goldman BH,Thomas CR Jr,et al. Cetuximab plus cisplatin,irinotecan,and thoracic tadiotherapy as definitive treatment for locally advanced,unresectable esophageal cancer: a phase-Ⅱ study of the SWOG(S0414). J Thorac Oncol,2012,7:906-912. [27]Ferry DR,Anderson M,Beddard K,et al. A phase Ⅱ study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression,cellular,and clinical response. Clin Cancer Res,2007,13:5869-5875. [28]Janmaat ML,Gallegos-Ruiz MI,Rodriguez JA,et al. Predictive factors for outcome in a phase Ⅱ study of gefitinib in second-line treatment of advanced esophageal cancer patients. J Clin Oncol,2006,24:1612-1619. [29]Dobelbower MC,Russo SM,Raisch KP,et al. Epidermal growth factor receptor tyrosine kinase inhibitor,erlotinib,and concurrent 5-fluorouracil,cisplatin and radiotherapy for patients with esophageal cancer: a phase Ⅰ study. Anticancer Drugs,2006,17:95-102. [30]Pande AU,Iyer RV,Rani A,et al. Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology,2007,73:281-289. [31]Folprecht G. Current medicinal treatment of metastasized colorectal carcinoma. Chirurg,2010,81:507-515. [32]Karapetis CS,Khambata-Ford S,Jonker DJ,et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med,2008,359:1757-1765. [33]Chen Y,Wu X,Bu S,et al. Promising outcomes of definitive chemoradiation and cetuximab for patients with esophageal squamous cell carcinoma. Cancer Sci,2012,103:1979-1984. [34]Safran H,DiPetrillo T,Nadeem A,et al. Trastuzumab,paclitaxel,cisplatin,and radiation for adenocarcinoma of the esophagus: a phase Ⅰ study. Cancer Invest,2004,22:670-677. [35]Yamazaki M,Yamashita Y,Kubo N,et al. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab. Oncol Rep,2012,28:49-54. [36]Shah MA,Jhawer M,Ilson DH,et al. Phase Ⅱ study of modified docetaxel,cisplatin,and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. Clin Oncol,2011,29:868-874. [37]Bendell JC,Meluch A,Peyton J,et al. A phase Ⅱ trial of preoperative concurrent chemotherapy/radiation therapy plus bevacizumab/erlotinib in the treatment of localized esophageal cancer. Clin Adv Hematol Oncol,2012,10:430-437. [38]Dawson SJ,Michael M,Biagi J,et al. A phase Ⅰ/Ⅱ trial of celecoxib with chemotherapy and radiotherapy in the treatment of patients with locally advanced oesophageal cancer. Invest New Drugs,2007,25:123-129. [39]Deasy BM,O′Sullivan-Coyne G,O′Donovan TR,et al. Cyclooxygenase-2 inhibitors demonstrate anti-proliferative effects in oesophageal cancer cells by prostaglandin E(2)-independent mechanisms. Cancer Lett,2007,256:246-258.
2013, Vol. 22 
